OncoMatch/Clinical Trials/NCT06347705
A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer
Is NCT06347705 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies 2141-V11 Antibody for prostate cancer.
Treatment: 2141-V11 Antibody — The purpose of this study is to see whether combining 2141-V11 with various standard treatments is an effective treatment approach for prostate cancer. 2141-V11 works by activating the immune system to find and kill cancer cells. Researchers will look at whether this treatment approach is able to completely get rid of cancer in participants, and they will check for the presence of minimal residual disease (MRD) in participants. MRD is a small number of cancer cells that can be detected in the body after treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Demographics
Prior therapy
Cannot have received: prostate surgery
Prior prostate surgery, pelvic lymph node dissection, radiation therapy, or focal therapy as a treatment for prostate cancer or benign prostatic disease.
Cannot have received: pelvic lymph node dissection
Prior prostate surgery, pelvic lymph node dissection, radiation therapy, or focal therapy as a treatment for prostate cancer or benign prostatic disease.
Cannot have received: radiation therapy
Prior prostate surgery, pelvic lymph node dissection, radiation therapy, or focal therapy as a treatment for prostate cancer or benign prostatic disease.
Cannot have received: focal therapy
Prior prostate surgery, pelvic lymph node dissection, radiation therapy, or focal therapy as a treatment for prostate cancer or benign prostatic disease.
Cannot have received: androgen deprivation therapy (GnRH antagonist, GnRH agonist, ARSI)
Exception: initiated >12 weeks before enrollment
Current ADT with GnRH antagonist/agonist and/or ARSI initiated >12 weeks enrollment.
Cannot have received: cytotoxic chemotherapy for prostate cancer
Prior cytotoxic chemotherapy for prostate cancer
Cannot have received: prostate cancer metastasis-directed therapies
Exception: other than described above
Prior prostate cancer metastasis-directed therapies other than described above.
Lab requirements
Blood counts
ANC ≥1500/µl (≥1000/µl if benign ethnic neutropenia); Hemoglobin ≥9 g/dL; Platelet count ≥100,000/µl
Kidney function
Creatinine Clearance >45 mL/min (Cockcroft-Gault Formula)
Liver function
Total Bilirubin ≤ 1.8 mg/dl (Gilbert's syndrome exception: direct bilirubin ≤1.5 × ULN); SGOT (AST) ≤ 92.5 U/L; SGPT (ALT) ≤ 137 U/L; Baseline moderate and severe hepatic impairment (Child Pugh Class B & C) excluded
Cardiac function
Clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or NYHA Class III or IV heart disease or cardiac ejection fraction < 50% at baseline, or clinically significant ventricular arrhythmias within 6 months prior to treatment start.
Adequate bone marrow, hepatic, and renal function, as evidenced within 28 days prior to treatment start by: ANC ≥1500/µl (≥1000/µl if benign ethnic neutropenia) Hemoglobin ≥9 g/dL Platelet count ≥100,000/µl Creatinine Clearance >45 mL/min Total Bilirubin ≤ 1.8 mg/dl (Note: In participants with Gilbert's syndrome, if total bilirubin is 1.8 mg/dL, measure direct and indirect bilirubin and if direct bilirubin is ≤1.5 × ULN, participant may be eligible) SGOT (AST) ≤ 92.5 U/L SGPT (ALT) ≤ 137 U/L; Baseline moderate and severe hepatic impairment (Child Pugh Class B & C) excluded; Cardiac: see exclusion criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited protocol activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06347705 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior prostate surgery, pelvic lymph node dissection, radiation therapy disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages